Highlights
- Market Cap
- $14.22B
- Enterprise Value
- $13.67B
- EPS (TTM)
- -$3.80
- Total Revenue (TTM)
- $362.37M
- Gross Profit (TTM)
- $357.09M
- EBITDA (TTM)
- -$581.79M
- Year Range
- $28.33 - $84.94
- Target Price
- $98.23
- ROA (TTM)
- -77.45%
- ROE (TTM)
- 34.91%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BridgeBio Pharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
BridgeBio Pharma, Inc. (BBIO) has returned -2.92% so far this year and 114.81% over the past 12 months.
BridgeBio Pharma, Inc.
- 1D
- 7.06%
- 1M
- 11.70%
- YTD
- -2.92%
- 6M
- 42.97%
- 1Y
- 114.81%
- 3Y*
- 64.84%
- 5Y*
- 4.58%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jun 27, 2019, BBIO's average daily return is +0.21%, while the average monthly return is +3.34%. At this rate, your investment would double in approximately 1.8 years.
Historically, 54% of months were positive and 46% were negative. The best month was Jul 2023 with a return of +103.6%, while the worst month was Dec 2021 at -58.8%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BBIO closed higher 50% of trading days. The best single day was Jul 17, 2023 with a return of +75.9%, while the worst single day was Dec 27, 2021 at -72.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.02% | -13.96% | 11.70% | -2.92% | |||||||||
| 2025 | 24.67% | 2.02% | -0.95% | 10.96% | -10.71% | 26.07% | 9.47% | 9.50% | 0.35% | 20.60% | 14.96% | 6.22% | 178.75% |
| 2024 | -15.06% | -0.41% | -9.46% | -17.14% | 9.33% | -9.57% | 2.45% | 7.32% | -8.58% | -8.05% | 15.72% | 1.29% | -32.03% |
| 2023 | 21.78% | 23.06% | 45.18% | -12.42% | -5.51% | 25.36% | 103.55% | -14.57% | -11.84% | -1.25% | 10.25% | 40.61% | 429.79% |
| 2022 | -40.83% | -20.97% | 30.13% | -20.99% | -14.84% | 32.94% | -4.63% | 21.25% | -5.33% | 4.93% | -10.16% | -18.68% | -54.32% |
| 2021 | -20.18% | 24.52% | -12.85% | -9.22% | 5.87% | 2.97% | -12.32% | -6.25% | -6.47% | 5.36% | -17.98% | -58.81% | -76.54% |
Benchmark Metrics
BridgeBio Pharma, Inc. has an annualized alpha of 40.37%, beta of 1.35, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since June 28, 2019.
- This stock captured 125.46% of S&P 500 Index gains and 112.63% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 40.37%
- Beta
- 1.35
- R²
- 0.10
- Upside Capture
- 125.46%
- Downside Capture
- 112.63%
Return for Risk
Risk / Return Rank
BBIO ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and compare them to a chosen benchmark (S&P 500 Index).
| BBIO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.37 | 0.90 | +1.48 |
Sortino ratioReturn per unit of downside risk | 2.94 | 1.39 | +1.55 |
Omega ratioGain probability vs. loss probability | 1.40 | 1.21 | +0.19 |
Calmar ratioReturn relative to maximum drawdown | 5.51 | 1.40 | +4.11 |
Martin ratioReturn relative to average drawdown | 16.20 | 6.61 | +9.59 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BBIO risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the BridgeBio Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BridgeBio Pharma, Inc. was 92.80%, occurring on May 11, 2022. Recovery took 894 trading sessions.
The current BridgeBio Pharma, Inc. drawdown is 7.07%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.8% | Feb 9, 2021 | 317 | May 11, 2022 | 894 | Dec 3, 2025 | 1211 |
| -65.45% | Dec 24, 2019 | 58 | Mar 18, 2020 | 175 | Nov 24, 2020 | 233 |
| -44.53% | Sep 4, 2019 | 31 | Oct 16, 2019 | 25 | Nov 20, 2019 | 56 |
| -21.99% | Jan 4, 2021 | 17 | Jan 27, 2021 | 8 | Feb 8, 2021 | 25 |
| -20.25% | Jan 23, 2026 | 10 | Feb 5, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BridgeBio Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BridgeBio Pharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BBIO relative to other companies in the Biotechnology industry. Currently, BBIO has a P/S ratio of 39.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |